J 2014

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

POUR, Luděk, Sabina ŠEVČÍKOVÁ, Henrieta GREŠLIKOVÁ, Renata KUPSKÁ, Petra MÁJKOVÁ et. al.

Basic information

Original name

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

Authors

POUR, Luděk (203 Czech Republic, guarantor, belonging to the institution), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Henrieta GREŠLIKOVÁ (703 Slovakia, belonging to the institution), Renata KUPSKÁ (203 Czech Republic, belonging to the institution), Petra MÁJKOVÁ (203 Czech Republic, belonging to the institution), Lenka ZAHRADOVÁ (203 Czech Republic), Viera SANDECKÁ (203 Czech Republic), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Petr KUGLÍK (203 Czech Republic, belonging to the institution) and Roman HÁJEK (203 Czech Republic, belonging to the institution)

Edition

Haematologica/the hematology journal, Fondazione Ferrata Storti, 2014, 0390-6078

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.814

RIV identification code

RIV/00216224:14110/14:00075357

Organization unit

Faculty of Medicine

DOI

UT WoS

000336253900030

Keywords in English

alpha interferon; bortezomib; lenalidomide; melphalan; thalidomide

Tags

Tags

International impact, Reviewed
Změněno: 15/7/2014 14:51, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Even in the era of new drugs, multiple myeloma patients with extramedullary relapse have a poor prognosis. Our goal was to analyze the frequency and outcome of extramedullary relapse occurring in relapsed multiple myeloma patients. In total, we analyzed the prognosis of 226 relapsed multiple myeloma patients treated between 2005 and 2008 and evaluated them for presence of extramedullary relapse. We found evidence of extramedullary relapse in 24% (55 of 226) of relapsed multiple myeloma patients. In 14% (32 of 226) of patients, the lesions were not adjacent to the bone, while extramedullary relapse adjacent to the bone was documented in 10% (23 of 226) of cases. Patients without extramedullary relapse had significantly longer overall survival than patients with extramedullary relapse (109 vs. 38 months; P<0.001). Moreover, patients with soft tissue-related extramedullary relapse had significantly poorer overall survival compared to bone-related extramedullary relapse patients (30 vs. 45 months; P=0.022). Also, overall survival from diagnosis was as low as five months for soft tissue-related extramedullary relapse patients when compared to 12 months overall survival for bone-related extramedullary relapse. This is the first study that shows a significant difference in prognosis for different types of extramedullary relapse. If the extramedullary myeloma infiltration was not bone-related, overall survival after relapse was extremely short (5 months).

Links

MSM0021622434, plan (intention)
Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
MUNI/11/InGA17/2012, interní kód MU
Name: MikroRNA v patogenezi extramedulárního relapsu mnohočetného myelomu
Investor: Masaryk University
NT11154, research and development project
Name: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu
Investor: Ministry of Health of the CR